Engflag

Exoderil 1%

Quick links to important sections

Exoderil 1%

Exoderil 1__EN

Method of action: Anti-Inflammatory

Treatment option: Jock Itch, Empeines, Shingles, Pityriasis Versicolor, Athlete'S Foot

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Exoderil 1%

What is Exoderil 1%? Overview of Identity and Type

This section provides a definitive explanation of Exoderil 1% (Naftifine Hydrochloride), establishing its classification, composition, and general purpose without detailing specific usage instructions or adverse effects.

Property Description
Active ingredient Naftifine Hydrochloride
Form Topical Solution or Cream
Pharmacological class Antifungal Agent (Allylamine group)
Common use Addressing external fungal infections
Origin Synthetic Compound

1. Defining Exoderil 1%: Identity, Classification, and Composition

Exoderil 1% is a topical antifungal medicine, whose active ingredient is the synthetic compound Naftifine Hydrochloride, belonging to the Allylamine class of antifungal agents. The product is a single-entity product designed exclusively for external application. The core component, Naftifine, is an Allylamine derivative. This classification signifies a targeted mechanism of action, distinguishing it from older antifungal drug classes. The medicinal entity, Naftifine Hydrochloride, has a high affinity for the target enzyme in fungal cells.

2. Physical Form and Delivery: Topical Solution or Cream

The formulation Exoderil 1% is prepared for external use, available as a topical solution or a cream, enabling application directly to the infected skin or nail surface. This topical route of administration is designed to concentrate the active substance where the fungus is present, a feature utilized for superficial infections like tinea. The solution utilizes an hydroalcoholic base, while the cream is made with a lipophilic base, with both vehicles designed to facilitate the permeation of the antifungal agent. Naftifine is utilized in these various topical formulations. This means the medicine is designed to be successfully delivered to the affected area using different external bases.

3. General Purpose and Core Antifungal Action

The general purpose of Exoderil 1% is to address the underlying cause of external fungal problems by selectively interfering with the growth and survival of the fungal cell. The Allylamine agent achieves this through both fungicidal action (actively killing the fungus) and fungistatic action (preventing further growth), providing a comprehensive approach. Furthermore, Naftifine is described as possessing a secondary, localized anti-inflammatory effect. This additional property provides the practical benefit of helping to reduce secondary symptoms such as redness and irritation often associated with the fungal presence. Exoderil's positioning as a readily available topical solution or cream makes it a typical choice for consumers seeking relief from common fungal skin issues.

What side effects are possible with Exoderil 1%?

Possible Side Effects and Safety Information

The official safety profile for Exoderil 1% (Naftifine Hydrochloride) is primarily characterized by adverse reactions localized to the area of application. Regulatory documents classify these effects, which are usually transient and may be more pronounced at the beginning of treatment.

Officially Classified Adverse Reactions

The majority of documented effects fall under the Skin and subcutaneous tissue disorders and the General disorders and administration site conditions system-organ classes.

Frequency Classification Documented Reactions
Common (ge 1/100 to < 1/10) Local irritation, dryness, erythema (redness), transient burning sensation at the application site.
Not Known (Cannot be estimated) Hypersensitivity reactions (allergic reactions), contact dermatitis.

Serious Reactions and Safety Limitations

While the medicine has low systemic absorption, official labeling includes the potential for Hypersensitivity Reactions (serious allergic responses) as a safety concern, even if the frequency is unquantified ('Not Known').

The regulatory label mandates that the medicine is strictly for external use only. Contact must be avoided with the eyes and mucous membranes. Caution is also advised when applying the product to areas of open wounds or broken skin.

Specific safety statements are included regarding certain populations. Safety has not been fully established in the pediatric population (under 12 years). Official documents also advise caution concerning use during pregnancy and lactation due to limited available safety data.

Overdose and Emergency Response

Overdose and When to Seek Help

Exoderil 1% (Naftifine Hydrochloride) is a topical antifungal medication with minimal systemic absorption when used as directed. Consequently, official government regulatory documents primarily address the risk and required response protocols for accidental oral ingestion, rather than overdose from excessive topical application.

Official Regulatory Overdose Information

Overdose Scenario Required Emergency Action
Accidental oral ingestion Call a Poison Control Center immediately.
Accidental ingestion leading to serious symptoms Call 911 or local emergency services right away.

Serious symptoms that mandate calling emergency services include trouble breathing or passing out (loss of consciousness).

Management and Antidote

Official labeling indicates that no specific antidote for Naftifine overdose is available. Management following accidental ingestion is symptomatic and supportive, guided by the instructions received from a Poison Control Center or medical professionals.

For signs of local irritation or sensitivity resulting from topical application, the medication should be discontinued. Patients should seek medical advice for managing the resulting local reaction.

This information is strictly based on the guidance provided in authoritative regulatory prescribing documents.

Therapeutic Uses of Exoderil 1%

Easing General Symptomatic Discomfort

The medicine is relevant in contexts involving inflammatory or irritative states and is commonly used to help with certain symptoms related to physical discomfort. The active ingredient is utilized in the symptomatic management of conditions such as athlete's foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis). It is commonly used when short-term symptomatic assistance is needed, assisting with addressing symptom clusters that may become intense or disruptive and contributing to improved day-to-day comfort.

Support for Episodic or Fluctuating Symptom Patterns

This medicine is considered relevant in conditions characterized by periods of heightened symptoms. It offers symptomatic relief that helps patients cope more steadily with difficult episodes and supports general well-being during symptomatic phases. It supports the patient during difficult episodes by easing distress. It assists with maintaining functional stability when symptoms escalate temporarily.

Addressing Symptoms Interfering with Daily Stability

Exoderil 1% is applied in scenarios where additional management of discomfort is required, specifically when groups of symptoms interfere with daily functioning. It provides supportive relief that helps ease the overall burden of symptoms, making it helpful in situations requiring temporary assistance in symptom stabilization.

Quick Fact: May assist with symptoms related to itching

Regulatory References

  1. NIH DailyMed Drug Label

Eligibility and Restrictions for Use

Who Can and Cannot Use Exoderil 1%?

This section outlines the official population eligibility criteria for Exoderil 1% (Naftifine Hydrochloride) as defined in government regulatory labeling.

Populations with Eligibility Limitations

Classification Status According to Regulatory Documents
Absolute Contraindication Individuals with known hypersensitivity (allergy) to naftifine hydrochloride or any component of the formulation.
Pediatric Use (< 12 years) Safety and effectiveness are not established for the 1% formulation in children younger than 12 years of age.
Geriatric Use (65 years) Clinical studies did not include sufficient numbers of older adults to determine if they respond differently than younger subjects.
Pregnancy and Lactation Use is conditional; only if clearly needed and the potential benefit justifies the potential risk. Caution is recommended for nursing mothers.

Official Restrictions on Use

Exoderil 1% is strictly for topical use only. It is not for ophthalmic, oral, or intravaginal use as stated in official product labeling. The medicine is primarily intended for use by adults and adolescents 12 years of age for labeled indications, subject to the limitations noted above.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction scope

Category Official Regulatory Status (Topical 1% Formulation)
Medicinal product categories with documented interactions None listed in official regulatory documents due to the nature of the formulation.
Specific interacting medicines None listed in official regulatory documents.
Mechanistic basis of interactions The official basis for the lack of documented systemic interaction is the minimal systemic absorption and low systemic availability of Naftifine after topical application.
Timing-based interaction rules None documented in regulatory sources for co-administration with systemic or other topical medicines.
Food, alcohol, herbal product interactions No interactions with food, alcohol, or herbal products are officially documented.
Interaction-related restrictions No specific systemic drug–drug restrictions are documented based on systemic interaction risk.

Interaction classifications (high-level)

Classification Regulatory Status
Interaction severity classification Officially defined as a negligible risk of clinically significant systemic drug-drug interaction due to low plasma concentrations.
Regulatory basis Based on Pharmacokinetic Studies cited in official government prescribing information (e.g., FDA Prescribing Information and international SmPC documents).
Interaction-context constraints Constrained by the Topical Route of Administration, which results in low systemic exposure and eliminates the need for typical interaction warnings associated with oral medications.

Resulting interaction structure

Official interaction statements:

  • Following topical administration of Naftifine Hydrochloride 1%, systemic absorption is minimal.
  • The resulting low plasma concentrations indicate that Naftifine is unlikely to affect the clearance of co-administered systemic drugs.
  • Official regulatory labeling does not document or list specific systemic drug-drug interactions or metabolic interactions for the topical formulation.

The overall interaction structure, as presented in government regulatory documents, is defined by the negligible risk of systemic interaction. This official classification stems from the documented finding of minimal absorption after external application. Consequently, the regulatory text does not specify any interacting medicines, interaction-based contraindications, or mandatory timing separation rules. This profile reflects the lack of clinically significant systemic drug-drug or drug-substance interactions documented in authoritative regulatory sources.

Mechanism of Action

How Exoderil 1% Works: Mechanism of Action

Core Mechanistic Domain: Targeting Fungal Ergosterol Biosynthesis

The primary biological action of Exoderil (naftifine) is the non-competitive inhibition of the fungal enzyme squalene 2,3-epoxidase. This targets the essential pathway responsible for creating ergosterol, the vital structural component of the fungal cell membrane, resulting in compromised cellular function.

Mechanistic Cascade: Dual Effect (Toxicity and Depletion)

The mechanism operates through a two-step cascade: it causes toxic squalene accumulation within the fungal cell while simultaneously enforcing ergosterol depletion in the cell membrane. This combination initiates cellular compromise, leading to the biological outcomes of fungicidal and fungistatic activity.

Modulating Local Inflammatory Signaling

In addition to its direct anti-fungal action, naftifine engages a separate mechanistic domain by modulating the host's local inflammatory signaling. It achieves this by inhibiting the production of certain inflammatory mediators and reducing the migration of immune cells. This mechanism produces the physiological consequence of reduced localized inflammatory signaling, including suppressed erythema and pruritus.

Dosage and Administration Information

General Administration Guidelines for Exoderil 1% (Naftifine Hydrochloride)

Exoderil 1% is designated strictly for topical use, meaning the formulation must be applied externally and should not be used in the eyes (ophthalmic), mouth (oral), or vagina (intravaginal).

Standard Regimen and Frequency

The administration pattern for this antifungal preparation is defined by its formulation. The 1% cream is typically applied once a day (q.d.). Dosing for the 1% gel formulation, where available, may differ, with regimens often based on twice-daily application. Both formulations involve applying a sufficient quantity of the product to create a thin layer over the area of concern.

Procedural Application and Coverage

Standard instructions specify that the application must cover the visibly affected skin and must extend beyond the area of concern to include an approximate 1/2 inch margin of surrounding, healthy skin. The product should be applied with gentle massage. Following the application, the hands should be washed immediately. Product labeling also advises against the use of occlusive dressings or wrappings over the treated area unless otherwise instructed.

Duration and Population Rules

Treatment is generally maintained for up to four weeks. If no clinical improvement is observed after this four-week course, the patient's condition should be re-evaluated. Regarding high-level population rules, the safety and effectiveness in pediatric patients have not been established for the 1% cream formulation.

Recent Clinical Evidence

Evidence for Superficial Dermatophyte Infections

Research into Exoderil 1% (Naftifine Hydrochloride) was studied for its approved uses, which include fungal skin conditions such as Tinea Pedis (athlete's foot), Tinea Cruris (jock itch), and Tinea Corporis (ringworm). The research base includes Randomized Controlled Trials (RCTs). These short-term trials often compared the medicine against a non-medicated application vehicle to determine if patterns of change were apparent during the observation period.

In these research settings, studies monitored several key outcomes related to how the fungal infection and outcomes related to physical discomfort evolved. The trials focused on subjects with laboratory-confirmed infections. Findings describe patterns observed in the studies over the short-term study periods, with research exploring symptom changes and fungal status after the standard application time.

How Researchers Measured Study Outcomes

When clinical studies examined the effects of the medicine, they relied on two main ways to track changes. The first is Mycological Cure, which is a laboratory outcome where tests are conducted to track the absence of detectable fungus. This measure tracks the reported absence of detectable fungus within the studied area.

The second key measure is Clinical Cure. This involves assessing patient-reported outcomes describing perceived discomfort and the visible signs of the infection. Researchers used scoring systems to track changes in outcomes linked to inflammatory or irritative states, such as the severity of scaling, redness (erythema), and itching (pruritus). The collected data explored patterns related to how symptoms evolved in the observed populations during the defined study interval.

Long-Term Research and Durability of Response

Clinical trials for this medicine explored short-term symptom changes and typically included a follow-up duration that extended beyond the final day the medication was applied. In many cases, patients were observed in the study setting for a total period of about four to six weeks. This extended observation period was evaluated in studies to track the status of the infection at a defined interval following the end of the studied application period. However, evidence is limited for understanding infection relapse rates over extended periods (many months or years) after the initial treatment was evaluated in the study subjects.

How should Exoderil 1% be stored and disposed of?

The storage and disposal of Exoderil 1% (naftifine hydrochloride 1% topical preparations) must strictly follow the conditions specified in official regulatory labeling.

Required Storage Conditions

Item Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F). Excursions up to 30 C (86 F) are permitted for brief periods.
Container Rule Keep the medicine in its original container and do not subject it to temperatures outside the required range (e.g., do not freeze).
Child Safety Keep this and all medications out of the reach of children.
Handling Note The product is FOR TOPICAL USE ONLY. NOT FOR OPHTHALMIC USE.

Disposal Instructions

Unused or expired Exoderil 1% must be disposed of safely. The official requirement is to discard the product according to local regulations for medicinal waste, ensuring it remains inaccessible to children and pets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagAustria

flagBosnia & Herzegowina

flagEgypt

Equivalent of Exoderil 1% found in:

A-Z Index: